Last updated: July 1, 2026
Takeda Pharmaceuticals U.S.A., Inc. v. Granules Pharmaceuticals Inc. (1:17-cv-01019): Litigation Summary, Patent Issues, and Exposure Analysis
Takeda Pharmaceuticals U.S.A., Inc. v. Granules Pharmaceuticals Inc., No. 1:17-cv-01019 (D. Del.), is a U.S. Hatch-Waxman patent-infringement case tied to Takeda’s branded drug patent estate and Granules’ proposed generic entry. The dispute is framed as a patent validity and infringement fight over one or more Orange Book-listed patents; the practical value for generics is the availability of “design-around” freedom-to-market if asserted claims fail or patents expire or are not enforceable.
No complete case caption details, asserted patent list, patents-in-suit, ANDA number, litigation posture (Markman, summary judgment, trial), or settlement terms are provided in the prompt. Without those specifics, a complete and accurate litigation summary cannot be produced.
Given the constraint that a response must be complete and accurate, the requested litigation summary and analysis cannot be generated from the information available.